Related references
Note: Only part of the references are listed.Results of a Randomized, Double-Blind Study of Romiplostim Versus Placebo in Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome and Thrombocytopenia
Aristoteles Giagounidis et al.
CANCER (2014)
Association between Acute Myelogenous Leukemia and Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia
Yasuo Oshima et al.
INTERNAL MEDICINE (2013)
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine
Peter L. Greenberg et al.
LEUKEMIA & LYMPHOMA (2013)
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
Eunice S. Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
Hagop M. Kantarjian et al.
BLOOD (2010)
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Hagop Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes
Ramon V. Tiu et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
The incidence and impact of thrombocytopenia in myelodysplastic syndromes
Hagop Kantarjian et al.
CANCER (2007)
Estimating the prevalence and pre-test likelihood of myelodysplasia: a retrospective review of bone marrow histopathology in 322 cases of unexplained cytopenia(s) in a teaching hospital
R. Buckstein et al.
LEUKEMIA RESEARCH (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Platelet function and its clinical significance in the myelodysplastic syndromes
A Zeidman et al.
HEMATOLOGY JOURNAL (2004)
Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies
NM Heddle et al.
TRANSFUSION (2003)
Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses
HH Wu et al.
CANCER (2003)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
